| |
|
|
|
Nymox Pharmaceutical Corporation  
|
|
1.69 -0.04 (-0.02%) |
08-23 16:00 |
|
Open: |
1.72 |
Pre close: |
1.73 |
Target:
|
2.16
|
|
High: |
1.7373 |
Low: |
1.65 |
Resistance:
|
1.85
2.00
|
|
Volume: |
70,945 |
Market Cap: |
115M |
Support:
|
1.60
1.33
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
1.74
 |
MACD |
MACD(12,26):
|
0.01  |
|
MA(20): |
1.77 |
Signal(12,26,9): |
0.02 |
|
MA(100): |
1.72 |
Stochastic Oscillator |
%K(14,3):
|
31.67 |
|
MA(250): |
1.93 |
%D(3): |
37.50 |
|
Average Volume(K) |
3-Month: |
15007
|
52-Week |
High:
|
2.93 |
|
10-Days: |
7864 |
Low: |
1.25 |
|
RSI |
RSI(14):
|
46.46 |
Change(%): |
-32.9 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.172 |
Return on Equity (ttm) |
-238.8 |
Shares Out. (M) |
67.93 |
|
EPS Est. Current Year |
-0.200 |
Return on Assets (ttm) |
-106.9 |
Shares Float (M) |
37.64 |
|
EPS Est. Next Year |
-0.570 |
PEG Ratio |
0.00 |
% Held by Insiders |
41.49 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
-80.3 |
% Held by Institutions |
6.37 |
|
Forward EPS |
1.#IO |
Gross Profit (p.s.) |
0.002 |
Shares Short (K) |
1640 |
|
Book Value (p.s.) |
0.150 |
EBITDA (p.s.) |
-0.160 |
P/E |
-9.83 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
11.27 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-7.56 |
P/S |
0.00 |
|
Operating Margin |
-6161.58 |
Levered Free Cash Flow
(M) |
-3.90 |
P/CF |
-15.19 |
|
|
|
|
|
|
